Science

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

Coronavirus Conspiracy Theories in Psychedelia

Conspiracy theories are nothing new when it comes to psychedelia. But in the context of coronavirus, they've become significantly more harmful.

LSD Chemist William Leonard Pickard Has Been Released From Prison

LSD chemist and longtime drug war prisoner, William Leonard Pickard, was officially released from prison on July 27, 2020. Pickard had been locked down since 2000 and was slated to serve two life sentences without the possibility of parole.

We Need to Talk About MAPS Supporting The Police, The Military, and Violent White Supremacism

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacy, capitalism, and imperialism.

Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19

Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.

DARE to Resist White Supremacy and The Police American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christan Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins

With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

MDMA Expanded Access is almost here. What’s it all about?

The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

Will MDMA-assisted psychotherapy be covered by health insurance?

Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

How will MDMA be rescheduled in the future? You may be disappointed

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

The Future of MDMA: Phase 3 and Beyond

What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

Let’s Talk About Psychedelic-Induced Psychosis

Comedian Shane Mauss and Zendo Project's Ryan Beauregard on psychedelic-induced psychosis. “It was really easy once I got past the big video game, ‘Truman Show’ feeling, to get to a place of, ‘oh, that was all in my head. I was crazy.’"

Bunk Police Drug Testing

The Bunk Police is looking to destroy dishonesty in the drug market

If there are other harm-reduction organizations, such as DanceSafe, that are able to distribute test kits, then we won’t attend that event....the ones that refuse DanceSafe, we come in and do it anyways.

Intentionally-diverse MDMA research at University of Connecticut Cut Short

The research team at UConn studying MDMA-assisted psychotherapy for PTSD is now defunct.

psychedelic.support creates a network for psychedelic therapists

psychedelic.support could soon become a useful asset to anyone interested in the professional world of psychedelic-related therapy.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

Finally, there’s a group giving grants to students researching psychedelics

We talked with Johns Hopkins psychedelic researcher, Alan Kooi Davis, about the Source Research Foundation, a non-profit awarding grants to students researching psychedelics.

A Doctor Explains How Prescribing Ketamine For Depression Works

We spoke with an experienced psychiatrist about how exactly prescribing ketamine for depression works.

What happens when you give an octopus MDMA?

A team of researchers bathed octopuses in MDMA. Here's what they learned.

Cartoon Dystopia: 25I-NBOMe and Why You Should Test Your LSD

Like the vast majority of psychonauts, I didn’t use a chemical reagent to verify I was taking LSD, even though I had been active in harm reduction work for three years prior and was aware of testing kits.

I talked with Adam Strauss about Ketamine for OCD, Trip Sitters, and The Mushroom Cure Los Angeles

Before I met Adam I didn’t really know anyone with OCD. It was just an abstract concept to me. Like most people, I had the image of the stereotypical germaphobe who obsessively scrubs their hands in a futile attempt at washing the thousands of bacteria away.

For someone who hasn’t taken a psychedelic drug it can be difficult to imagine what it’s like.

Think of a glass of water: under normal circumstances you might think ‘I drink water when I’m thirsty’. But when consuming a psychedelic substance you might think ’water is the essence of life’.

Salvinorin A. Is it possible to have a truly powerful painkiller that is not addictive?

We Need New Drugs. The opioid epidemic gripping the United States has brought into public awareness a problem that has bedeviled the world of medical science for decades: is it possible to have a truly powerful painkiller that is not addictive?

Becoming a Psychedelic Researcher: Alan Kooi Davis

Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.

We talked with a researcher using psilocybin for cocaine addiction in Alabama

I came to a working hypothesis: at the center of the mystical experience is awe, wherein one is in the presence of something so great, so large, that it requires they completely reorder their mental structures - completely change the way they view reality.

We now call ‘bad trips’ ‘challenging experiences’. Here’s why that’s misguided.

Renaming adverse effects of psychedelic drugs as “challenging experiences” minimizes, almost trivializes, their negative effects.

Psychedelics and the Full-Fluency Phenomenon

I first discovered the potential psychedelics have for treating stuttering during an experience with psilocybin mushrooms.

Is ibogaine the cure for opioid addiction? It’s not that simple.

The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.

Ibogaine treatment comes with risks. We had a discussion about safety with medical providers.

The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.

How safe is ibogaine? We asked Clare Wilkins who has facilitated over 700 treatments

The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.

How Not to Do Ibogaine 101 with Juliana Mulligan

The Ibogaine Conversation Part 8 | This is not a do-it-at-home type thing.

Talking ibogaine research for opioid addiction with Thomas Kingsley Brown

The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.

Ibogaine presents unique challenges in how we approach harm reduction and treat addiction

The Ibogaine Conversation Part 1 | This series explores the unique challenges ibogaine presents in how we approach plant medicine, harm reduction, and treatment for addiction, through the lens of ibogaine researchers, providers, patients, and advocates from around the world.

Johns Hopkins studying effects of psilocybin on brains of long-term meditators

Are these states really similar? Many meditators have answered quite clearly, yes.

The State: The Opioid Epidemic

For anyone who remembers the Reagan Administration's awesome response to the '80s crack epidemic, the Trump plan may prompt discouraging deja vu.

Your Brain on Psychedelic Drugs

What is it about psychedelics that has the power to change lives for the better? The answer might lie in the unique ways that psychedelics interact with the brain.

The State: Friday, Oct 27, 2017

To get a vision of the future of psychedelics from a legal and regulatory perspective, the most useful thing to do might be to see what's happening already in the realm of weed.

Psychedelics and Mental Health

Depression. Anxiety. Addiction. Most everyone of us knows somebody who is battling such a condition. Talk therapies may help, but sometimes they don’t. Antidepressants may help, but sometimes they don’t. Some patients are of the opinion that antidepressants are like “Band-Aids” in the way that they never really tackle the underlying issues of their problems.

What’s so controversial about microdosing?

The incredible mainstream press microdosing has received has managed to avoid many discussions.

I was in the MAPS MDMA for PTSD study. It freed me from a childhood of abuse.

MDMA-assisted psychotherapy gave me the ability to feel compassion and empathy for myself.

Breathe. Breathe. Breathe. An Interview with Iker Puente on Holotropic Breathwork

Holotropic Breathwork is not just a breath technique. It was conceived as a non-drug way of accessing non-ordinary states of consciousness.

How Psychedelic Science Privileges Some, Neglects Others, and Limits Us All

There is an urgent need for cultural humility in psychedelic science in order to prevent it from falling into the same limiting, and often unethical, traps that we see in Western science and medicine.

The State: Tuesday, Sept 19, 2017

Welcome to the first edition of The State. This column will look at a few of the more noteworthy stories making waves in the psychedelic and reform spheres, and when appropriate, examine how they fit into a larger context.

Psychedelic cluster busting headache medication saves me. And it’s completely illegal

Cluster headaches to me feel like someone has my eyeball in their fist, steadily putting more and more pressure on it until it threatens to pop like a grape

Of Molecules and Minds: The Science of Ayahuasca

There’s a beauty and sense of wonder that comes from knowing how the world works, and the nature of the psychedelic experience dovetails almost perfectly with that awareness.

The latest piece on psychedelic science in the New York Times is dead wrong

First, the entire premise—that Schedule I status is the primary obstacle to research—is flat-out wrong.

Dennis McKenna on his ethnopharmacology conference 50 years in the making

It’s been 50 years since the last one. The original idea was to hold followups every 10 years. But the war on drugs came along, and they were never held. It’s time to take another look at the current state of the art.

Psychedelics Can’t be Tested Using Conventional Clinical Trials

Should these drugs become part of medicine cabinets from San Francisco to America’s heartland, it will be high time to develop drug tests that control for the cultural diversity of this country’s doctors and patients.

A Short History of Psychedelic Psychotherapy, Pt. 2

Let’s go forward in time through the government’s ban on psychedelics, and look how it has blossomed into the psychedelic renaissance.

A Short History of Psychedelic Psychotherapy, Pt. 1

Psychotherapy-assisted psychedelic experiences may revolutionize how we treat mental illness. The philosophy and techniques have evolved over the past 50 years.

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #3

Dose #3 was the most intense, powerful, horrendous, terrifying, awful experience of my life. In the end, it was all worth it. Conclusion to a 3-part series.

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #2

This time my dose was 45 mg of pure psilocybin. I took it and waited for the show to begin. There was fear and a sincere hope that this experience would not be as hellish. Pt 2

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #1

A 3-part series on one participant's high dose psilocybin experience in the Pharmacokinetics of Psilocybin in Normal Adult Volunteers study at the University of Wisconsin.

Precautions with Underground Psychedelic Therapy

In underground sessions, you’re taking a huge risk choosing to work with someone who may not have adequately prepared or may have dubious subconscious motivations.

Do psychedelics trigger neurogenesis? Here’s what we know.

What is neurogenesis? Do psychedelics really cause it? If they do, what doors might that open up?

Non-PTSD Uses for MDMA

MDMA has the potential of treating and reversing even the most pervasive of pathologies in the mental health world

How Does LSD Induce Short-Term Psychosis but Long-Term Optimism?

There’s only one way to find out – more scientific experiments.

Finding The Sweet Spot : At 62 I Had My First Dose Of Psilocybin At Johns Hopkins

A research program was seeking volunteers with a spiritual background to ingest a hallucinogen.

Winter Blues Got You Down? Try These Integrative Antidepressant Approaches

Here's some integrative antidepressant approaches that have low or no side effects and won't cost you an arm and a leg.

Union of Opposites: Trump Selects War Cabinet, Psychedelics Make Mainstream Waves

"We cannot imagine events that are connected non-causally and are capable of a non-causal explanation. But that does not mean that such events do not exist." Carl Jung

My First Psychedelic Experience at Johns Hopkins Changed My Life

It’s been more than six years since I participated in the Johns Hopkins Spirituality study, but it continues as the most life-changing event of my life.

Psychedelic Frontiers of Western Medicine

Johns Hopkins and Yale Schools of Medicine reviewed dozens of studies and recent trials on psychedelic compounds.

A Divine Encounter In The Johns Hopkins Psilocybin Study

"On Tuesday, you will be the only person in the U.S. who will be taking psilocybin legally.”

Canada Approves Legal Heroin For Severely Addicted Patients

Canada has amended its policies on heroin to allow doctors to prescribe the drug to patients suffering severe addiction.

Did Carl Sagan use LSD? We asked his son

I offered to take it with him, and suggested that the nearby greenery and scenery would be a good place to trip.

Comedian Adam Strauss on treating OCD with psilocybin mushrooms

Inspired by a scientific study showing that psilocybin mushrooms can potentially cure OCD, Adam Strauss embarked on vigilante psychopharmacology.

Patterning a World of Mushrooms: The Challenges of Co-Production

‘Co-production’ refers to processes in which a range of experts and non-experts are enrolled as researchers and attempt to generate knowledge together.

The Psychonaut’s Dilemma

During an earlier era of psychedelic research, the 1950s-70s, some scientists believed that in order to ethically administer psychedelics to others it was necessary to first experience them oneself.


Science

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

Coronavirus Conspiracy Theories in Psychedelia

Conspiracy theories are nothing new when it comes to psychedelia. But in the context of coronavirus, they've become significantly more harmful.

LSD Chemist William Leonard Pickard Has Been Released From Prison

LSD chemist and longtime drug war prisoner, William Leonard Pickard, was officially released from prison on July 27, 2020. Pickard had been locked down since 2000 and was slated to serve two life sentences without the possibility of parole.

We Need to Talk About MAPS Supporting The Police, The Military, and Violent White Supremacism

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacy, capitalism, and imperialism.

Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19

Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.

DARE to Resist White Supremacy and The Police American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christan Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins

With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

MDMA Expanded Access is almost here. What’s it all about?

The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

Will MDMA-assisted psychotherapy be covered by health insurance?

Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

How will MDMA be rescheduled in the future? You may be disappointed

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

The Future of MDMA: Phase 3 and Beyond

What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

Let’s Talk About Psychedelic-Induced Psychosis

Comedian Shane Mauss and Zendo Project's Ryan Beauregard on psychedelic-induced psychosis. “It was really easy once I got past the big video game, ‘Truman Show’ feeling, to get to a place of, ‘oh, that was all in my head. I was crazy.’"

Bunk Police Drug Testing

The Bunk Police is looking to destroy dishonesty in the drug market

If there are other harm-reduction organizations, such as DanceSafe, that are able to distribute test kits, then we won’t attend that event....the ones that refuse DanceSafe, we come in and do it anyways.

Intentionally-diverse MDMA research at University of Connecticut Cut Short

The research team at UConn studying MDMA-assisted psychotherapy for PTSD is now defunct.

psychedelic.support creates a network for psychedelic therapists

psychedelic.support could soon become a useful asset to anyone interested in the professional world of psychedelic-related therapy.

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

Finally, there’s a group giving grants to students researching psychedelics

We talked with Johns Hopkins psychedelic researcher, Alan Kooi Davis, about the Source Research Foundation, a non-profit awarding grants to students researching psychedelics.

A Doctor Explains How Prescribing Ketamine For Depression Works

We spoke with an experienced psychiatrist about how exactly prescribing ketamine for depression works.

What happens when you give an octopus MDMA?

A team of researchers bathed octopuses in MDMA. Here's what they learned.

Cartoon Dystopia: 25I-NBOMe and Why You Should Test Your LSD

Like the vast majority of psychonauts, I didn’t use a chemical reagent to verify I was taking LSD, even though I had been active in harm reduction work for three years prior and was aware of testing kits.

I talked with Adam Strauss about Ketamine for OCD, Trip Sitters, and The Mushroom Cure Los Angeles

Before I met Adam I didn’t really know anyone with OCD. It was just an abstract concept to me. Like most people, I had the image of the stereotypical germaphobe who obsessively scrubs their hands in a futile attempt at washing the thousands of bacteria away.

For someone who hasn’t taken a psychedelic drug it can be difficult to imagine what it’s like.

Think of a glass of water: under normal circumstances you might think ‘I drink water when I’m thirsty’. But when consuming a psychedelic substance you might think ’water is the essence of life’.

Salvinorin A. Is it possible to have a truly powerful painkiller that is not addictive?

We Need New Drugs. The opioid epidemic gripping the United States has brought into public awareness a problem that has bedeviled the world of medical science for decades: is it possible to have a truly powerful painkiller that is not addictive?

Becoming a Psychedelic Researcher: Alan Kooi Davis

Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.

We talked with a researcher using psilocybin for cocaine addiction in Alabama

I came to a working hypothesis: at the center of the mystical experience is awe, wherein one is in the presence of something so great, so large, that it requires they completely reorder their mental structures - completely change the way they view reality.

We now call ‘bad trips’ ‘challenging experiences’. Here’s why that’s misguided.

Renaming adverse effects of psychedelic drugs as “challenging experiences” minimizes, almost trivializes, their negative effects.

Psychedelics and the Full-Fluency Phenomenon

I first discovered the potential psychedelics have for treating stuttering during an experience with psilocybin mushrooms.

Is ibogaine the cure for opioid addiction? It’s not that simple.

The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.

Ibogaine treatment comes with risks. We had a discussion about safety with medical providers.

The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.

How safe is ibogaine? We asked Clare Wilkins who has facilitated over 700 treatments

The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.

How Not to Do Ibogaine 101 with Juliana Mulligan

The Ibogaine Conversation Part 8 | This is not a do-it-at-home type thing.

Talking ibogaine research for opioid addiction with Thomas Kingsley Brown

The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.

Ibogaine presents unique challenges in how we approach harm reduction and treat addiction

The Ibogaine Conversation Part 1 | This series explores the unique challenges ibogaine presents in how we approach plant medicine, harm reduction, and treatment for addiction, through the lens of ibogaine researchers, providers, patients, and advocates from around the world.

Johns Hopkins studying effects of psilocybin on brains of long-term meditators

Are these states really similar? Many meditators have answered quite clearly, yes.

The State: The Opioid Epidemic

For anyone who remembers the Reagan Administration's awesome response to the '80s crack epidemic, the Trump plan may prompt discouraging deja vu.

Your Brain on Psychedelic Drugs

What is it about psychedelics that has the power to change lives for the better? The answer might lie in the unique ways that psychedelics interact with the brain.

The State: Friday, Oct 27, 2017

To get a vision of the future of psychedelics from a legal and regulatory perspective, the most useful thing to do might be to see what's happening already in the realm of weed.

Psychedelics and Mental Health

Depression. Anxiety. Addiction. Most everyone of us knows somebody who is battling such a condition. Talk therapies may help, but sometimes they don’t. Antidepressants may help, but sometimes they don’t. Some patients are of the opinion that antidepressants are like “Band-Aids” in the way that they never really tackle the underlying issues of their problems.

What’s so controversial about microdosing?

The incredible mainstream press microdosing has received has managed to avoid many discussions.

I was in the MAPS MDMA for PTSD study. It freed me from a childhood of abuse.

MDMA-assisted psychotherapy gave me the ability to feel compassion and empathy for myself.

Breathe. Breathe. Breathe. An Interview with Iker Puente on Holotropic Breathwork

Holotropic Breathwork is not just a breath technique. It was conceived as a non-drug way of accessing non-ordinary states of consciousness.

How Psychedelic Science Privileges Some, Neglects Others, and Limits Us All

There is an urgent need for cultural humility in psychedelic science in order to prevent it from falling into the same limiting, and often unethical, traps that we see in Western science and medicine.

The State: Tuesday, Sept 19, 2017

Welcome to the first edition of The State. This column will look at a few of the more noteworthy stories making waves in the psychedelic and reform spheres, and when appropriate, examine how they fit into a larger context.

Psychedelic cluster busting headache medication saves me. And it’s completely illegal

Cluster headaches to me feel like someone has my eyeball in their fist, steadily putting more and more pressure on it until it threatens to pop like a grape

Of Molecules and Minds: The Science of Ayahuasca

There’s a beauty and sense of wonder that comes from knowing how the world works, and the nature of the psychedelic experience dovetails almost perfectly with that awareness.

The latest piece on psychedelic science in the New York Times is dead wrong

First, the entire premise—that Schedule I status is the primary obstacle to research—is flat-out wrong.

Dennis McKenna on his ethnopharmacology conference 50 years in the making

It’s been 50 years since the last one. The original idea was to hold followups every 10 years. But the war on drugs came along, and they were never held. It’s time to take another look at the current state of the art.

Psychedelics Can’t be Tested Using Conventional Clinical Trials

Should these drugs become part of medicine cabinets from San Francisco to America’s heartland, it will be high time to develop drug tests that control for the cultural diversity of this country’s doctors and patients.

A Short History of Psychedelic Psychotherapy, Pt. 2

Let’s go forward in time through the government’s ban on psychedelics, and look how it has blossomed into the psychedelic renaissance.

A Short History of Psychedelic Psychotherapy, Pt. 1

Psychotherapy-assisted psychedelic experiences may revolutionize how we treat mental illness. The philosophy and techniques have evolved over the past 50 years.

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #3

Dose #3 was the most intense, powerful, horrendous, terrifying, awful experience of my life. In the end, it was all worth it. Conclusion to a 3-part series.

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #2

This time my dose was 45 mg of pure psilocybin. I took it and waited for the show to begin. There was fear and a sincere hope that this experience would not be as hellish. Pt 2

I received the largest dose of psilocybin ever administered in a published FDA study. Dose #1

A 3-part series on one participant's high dose psilocybin experience in the Pharmacokinetics of Psilocybin in Normal Adult Volunteers study at the University of Wisconsin.

Precautions with Underground Psychedelic Therapy

In underground sessions, you’re taking a huge risk choosing to work with someone who may not have adequately prepared or may have dubious subconscious motivations.

Do psychedelics trigger neurogenesis? Here’s what we know.

What is neurogenesis? Do psychedelics really cause it? If they do, what doors might that open up?

Non-PTSD Uses for MDMA

MDMA has the potential of treating and reversing even the most pervasive of pathologies in the mental health world

How Does LSD Induce Short-Term Psychosis but Long-Term Optimism?

There’s only one way to find out – more scientific experiments.

Finding The Sweet Spot : At 62 I Had My First Dose Of Psilocybin At Johns Hopkins

A research program was seeking volunteers with a spiritual background to ingest a hallucinogen.

Winter Blues Got You Down? Try These Integrative Antidepressant Approaches

Here's some integrative antidepressant approaches that have low or no side effects and won't cost you an arm and a leg.

Union of Opposites: Trump Selects War Cabinet, Psychedelics Make Mainstream Waves

"We cannot imagine events that are connected non-causally and are capable of a non-causal explanation. But that does not mean that such events do not exist." Carl Jung

My First Psychedelic Experience at Johns Hopkins Changed My Life

It’s been more than six years since I participated in the Johns Hopkins Spirituality study, but it continues as the most life-changing event of my life.

Psychedelic Frontiers of Western Medicine

Johns Hopkins and Yale Schools of Medicine reviewed dozens of studies and recent trials on psychedelic compounds.

A Divine Encounter In The Johns Hopkins Psilocybin Study

"On Tuesday, you will be the only person in the U.S. who will be taking psilocybin legally.”

Canada Approves Legal Heroin For Severely Addicted Patients

Canada has amended its policies on heroin to allow doctors to prescribe the drug to patients suffering severe addiction.

Did Carl Sagan use LSD? We asked his son

I offered to take it with him, and suggested that the nearby greenery and scenery would be a good place to trip.

Comedian Adam Strauss on treating OCD with psilocybin mushrooms

Inspired by a scientific study showing that psilocybin mushrooms can potentially cure OCD, Adam Strauss embarked on vigilante psychopharmacology.

Patterning a World of Mushrooms: The Challenges of Co-Production

‘Co-production’ refers to processes in which a range of experts and non-experts are enrolled as researchers and attempt to generate knowledge together.

The Psychonaut’s Dilemma

During an earlier era of psychedelic research, the 1950s-70s, some scientists believed that in order to ethically administer psychedelics to others it was necessary to first experience them oneself.